FDA Moves Forward with Mail-back Envelopes for Opioid Analgesics Dispensed in Outpatient Settings

Agency Continues to Take Steps to Reduce New Cases of Opioid Use Disorder SILVER SPRING, Md., April 3, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration announced it is requiring manufacturers of opioid analgesics dispensed in outpatient settings to make prepaid mail-back…